AI Article Synopsis
- Secondary acute lymphoblastic leukemia (sALL) occurs in 2-10% of ALL cases and can develop after chemotherapy or radiotherapy for prior cancers, as seen in a 72-year-old woman whose sALL followed treatment for lymphoma.
- Genetic analysis revealed specific chromosomal rearrangements, particularly a fusion of the MLL and PRRC1 genes, which is a significant finding in the diagnosis of sALL.
- A review of 65 sALL cases showed many were linked to the MLL rearrangement, with a high correlation to patients having received topoisomerase II inhibitors during their initial cancer treatments, suggesting a potential cause for the secondary leukemia.
Article Abstract
Secondary acute lymphoblastic leukemia (sALL) following chemotherapy and/or radiotherapy of previous malignancies represents 2-10% of all cases of ALL. A 72-year-old female patient was diagnosed with acute lymphoblastic leukemia following chemotherapy for a diffuse large B cell lymphoma. Banding cytogenetics showed a t(t(5;11)(q23-31;q23) in 20 of the 21 metaphases examined and fluorescent in situ hybridization confirmed rearrangement of MLL. Long distance inverse-polymerase chain reaction revealed an in-frame fusion between 5'MLL and 3'PRRC1. Sixty-five cases of sALL associated with 11q23/MLL rearrangement, including 47 with a t(4;11)(q21;q23), were retrieved from the literature. Drug regimen used to treat the primary neoplasm was available for 54 patients; 52 had received a topoisomerase II inhibitor, known to induce MLL rearrangement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2014.08.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!